Quest Diagnostics Incorporated (DGX)
Healthcare · Medical - Diagnostics & Research · Data as of 2026-09-01
Bottom line
DGX is trading near its usual valuation, in the middle of its recent price range, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading near its usual range (Yellow)
DGX trades at 25× earnings, above its own 5-year average of 19× and roughly in line with similar healthcare companies we track (29×, 52 peers). That is roughly what the market has typically paid for this stock. Its free-cash-flow yield is about 4.5%. Its current multiple sits around the 98th percentile of its own last five years — near the top of its own range.
Price zones — In the middle of its recent range (Yellow)
At $236.22, the stock sits between its recent support and resistance levels. Over the past year DGX has traded between $171.18 and $247.19; its historical support zone sits near $225.32 and resistance near $247.19. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $171.18–$247.19 · 50-day average $225.32 · 200-day average $200.30
Money flow — No clear direction (Yellow)
Buying and selling volume in DGX have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.1× volume on down days over the last 30 sessions.
About the company
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients.
一句话结论
DGX 估值接近其惯常水平，处于近期价格区间的中部，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 处于其惯常的估值区间
DGX 目前的市盈率为 25×，高于其自身 5 年平均的 19×，并且大致持平于我们追踪的同类Healthcare公司（29×，52 家）。这大致就是市场以往为这只股票所付出的水平。其自由现金流收益率约为 4.5%。它当前的估值倍数大约位于自身过去五年分布的第 98 百分位——接近自身区间的顶部。
价格区间 — 处于近期区间的中部
目前价格为 $236.22，位于其近期的支撑位与阻力位之间。过去一年 DGX 的价格在 $171.18 到 $247.19 之间波动；其历史支撑区在 $225.32 附近，阻力区在 $247.19 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 方向不明确
DGX 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.1×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.